Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PAP/PSA-expressing arenaviral vectors HB-302/HB-301

An alternating, 2-vector replicating arenaviral combination agent composed of two genetically engineered replicating vectors: HB-301, which is based on the arenavirus lymphocytic choriomeningitis virus (LCMV), and HB-302, which is based on the arenavirus Pichinde virus (PICV), and both expressing the same transgenes encoding for the two prostate cancer-associated antigens prostatic acid phosphatase (PAP) and prostate specific antigen (PSA), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, the PAP/PSA-expressing arenaviral vectors HB-302/HB-301 express PSA and PAP peptides and cause antibody-mediated and cytotoxic T-lymphocyte (CTL)-mediated immune responses against prostate cancer cells expressing PSA and PAP.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:PAP/PSA-expressing arenaviral vectors HB-300
Code name:HB 300
HB-300
HB-301/HB-302
HB-302/HB-301
HB300
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search